Expanding Pharmaceutical Access Across West Africa Through Strategic Partnerships

We present a comprehensive and forward-looking pharmaceutical licensing, registration, and partnership framework tailored specifically for Senegal, Ivory Coast, and Mali, driven by the robust manufacturing and regulatory capabilities of Taj Pharma India Ltd. Our initiative is designed to support regional healthcare systems by enabling rapid market entry, sustainable supply, and long-term commercialization success across regulated and semi-regulated African markets.

Through our Unit-1 and Unit-2 manufacturing platforms at Sarigam, we offer a well-structured product grid covering ANDA-approved dossiers, stability-complete dossiers, near-term regulatory submissions, and advanced development pipelines across high-demand therapeutic segments.


Why Taj Pharma Is a Strategic Partner for West African Markets

WHO-GMP Manufacturing with Global Regulatory Alignment

We operate from a WHO-GMP, PIC/S, ISO 9001:2018 compliant manufacturing facility located at Sarigam, Gujarat, India. Our systems are aligned with ICH, USFDA, EMA, and emerging market regulatory expectations, ensuring that dossiers can be efficiently adapted for Senegal (DPM), Ivory Coast (DHP), and Mali (DNM) registration pathways.

End-to-End Capabilities

Our value proposition spans:

  • Finished dosage form manufacturing
  • ANDA-ready and adaptable CTD dossiers
  • Stability data generation
  • Lifecycle management and post-approval variations
  • Scalable commercial supply

This integrated approach minimizes risk, reduces time-to-market, and enhances long-term product viability.


Unit-1 Sarigam: Licensing & Partnership Grid for Immediate Opportunities

ANDA-Approved and Market-Ready Dossiers

Our Unit-1 portfolio includes commercially initiated products with strong regulatory maturity, making them ideal for fast-track registration and licensing in West Africa. These dossiers are suitable for:

  • Exclusive country licensing
  • Regional distribution agreements
  • Tender participation
  • Private and institutional market supply

Several products have already progressed to plant-level initiation, enabling short lead times and predictable supply continuity.

Flexible Partnership Models

We actively engage in:

  • Regional licensing agreements
  • Co-development partnerships
  • Commercialization alliances
  • Royalty-based or profit-sharing structures

Each model is structured to align with local market dynamics, pricing sensitivities, and regulatory frameworks.

Product NameBrand Name (TAJ Format)Therapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
PiracetamCEBROTAJNootropic / CNS AgentTablet400 mgI
PiracetamCEBROTAJNootropic / CNS AgentTablet800 mgI
SimethiconeFLATIXTAJAntiflatulentTablet400 mgI
Sitagliptin PhosphateSITAMEDTAJAntidiabetic (DPP-4 Inhibitor)Tablet50 mgIII
Sitagliptin PhosphateSITAMEDTAJAntidiabetic (DPP-4 Inhibitor)Tablet100 mgIII
SpironolactoneSPIROTONTAJDiuretic / Aldosterone AntagonistTablet25 mgII
Tamsulosin + DutasterideNEFROMAXTAJBPH TherapyTablet0.4 mg + 0.5 mgII
Ursodeoxycholic AcidLIVURSOTAJHepatobiliary AgentTablet300 mgII
VogliboseGLYBOSETAJAntidiabetic (α-Glucosidase Inhibitor)Mouth Dissolving Tablet0.2 mgIII
VogliboseGLYBOSETAJAntidiabetic (α-Glucosidase Inhibitor)Mouth Dissolving Tablet0.3 mgIII
IvabradineCARDIVRATAJ SRAntianginalSR Tablet10 mgII
IvabradineCARDIVRATAJ SRAntianginalSR Tablet15 mgII
Tadalafil + DapoxetineVIRONEXTAJErectile Dysfunction / PETablet10 mg + 30 mgII
Ornidazole + OfloxacinONZTAJAntiprotozoal / AntibioticTablet500 mg + 200 mgII
Metamizole SodiumMETCERATAJAnalgesic / AntipyreticTablet500 mgI
Aceclofenac + ParacetamolFENAMOLTAJAnalgesic / Anti-inflammatoryTablet100 mg + 500 mgII
Paracetamol (ER)APRADOLTAJ EXTENDAnalgesic / AntipyreticExtended-Release Tablet1000 mgI
Ascorbic Acid + Zinc + SeleniumVITONTAJ SRNutritional SupplementTablet500 mg + 2.2 mg + 60 mcgI

Unit-2 Product Expansion: Market-Driven Portfolio Development

In parallel, we are strategically expanding Unit-2 based on regional demand signals and partner inputs. Your market intelligence plays a critical role in shaping this pipeline.

Priority Products Under Evaluation for Unit-2

Market interest is invited for the following high-demand, chronic and specialty therapies:

  • Bumetanide Tablets – Loop diuretic with strong hospital and cardiology demand
  • Phenytoin Sodium ER Capsules – Essential anti-epileptic with long-term use patterns
  • Ursodeoxycholic Acid Capsules – High-value hepatology product
  • Valaciclovir Tablets – Broad antiviral application across acute and chronic indications

Early engagement allows partners to secure priority rights, influence pack configurations, and align pricing strategies.

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
DeferasiroxDEFERATAJIron ChelatorDispersible Tablet250 mg, 500 mgII
Biperiden HClBIPERITAJAntiparkinsonianTablet4 mgI
Vitamin C (Ascorbic Acid)VITCTAJNutritional / ImmunityChewable Tablet500 mgI
Loratadine + Ambroxol HClLORAMBTajAnti-allergic / ExpectorantTablet10 mg + 30 mgII
CiprofloxacinCIPROTAJAntibiotic (Fluoroquinolone)Tablet500 mgIV
TadalafilTADALATAJPDE-5 InhibitorTablet5 mg, 40 mgII
SildenafilSILDENATAJPDE-5 InhibitorTablet100 mgII
MebendazoleMEBENTAJAnthelminticTablet500 mgII
FluconazoleFLUCONTAJAntifungalTablet200 mgI
PraziquantelPRAZITAJAnthelminticTablet600 mgII
Mefloquine HClMEFLOTAJAntimalarialTablet250 mgII
Hydroxychloroquine SulfateHYDROXYTAJAntimalarial / DMARDTablet200 mgIII
Mesalamine PRMESALATAJ-PRAnti-inflammatory (IBD)Prolonged-Release Tablet1.2 gIII
FenbendazoleFENBENTAJAnthelminticTablet200 mgIV
OxcarbazepineOXCARTAJAntiepilepticTablet150 mg, 300 mgII
TinidazoleTINIDATAJAntiprotozoal / AntibioticTablet500 mgI
Atazanavir + RitonavirATAZARITAJAntiretroviral (HIV)TabletAs per FDCIV
Lopinavir + RitonavirLOPIRITAJAntiretroviral (HIV)TabletAs per FDCIV
BedaquilineBEDAQTAJAnti-tubercular (MDR-TB)Tablet100 mgII
PyrimethaminePYRIMTAJAntimalarialTablet25 mgII
Prazosin HClPRAZOTAJAlpha-blocker (CVS)Tablet1 mgI
Potassium IodidePOTIOTAJThyroid / Radiation ProtectionTablet30 mg, 130 mgIII
IvermectinIVERMITAJAntiparasiticTablet6 mg, 12 mg, 24 mgII
Itopride HClITOPRITAJProkineticTablet50 mgI
MethotrexateMETHOTAJAntimetabolite / ImmunosuppressantTablet2.5 mgIII
Micronized Purified Flavonoid FractionFLAVOTAJVascular / CVTablet500 mgIV
Eperisone SREPERITAJ-SRMuscle RelaxantSustained-Release Tablet150 mgI
Xanthinol Nicotinate SRXANTHITAJ-SRPeripheral VasodilatorSR Tablet500 mgIII
ChlorthalidoneCHLORTAJThiazide-like DiureticTablet25 mgIV
PentoxifyllinePENTOXTajHemorheologic AgentTablet400 mgI
Pyridoxine HCl (Vitamin B6)PYRITAJVitaminTablet50 mgI
CaptoprilCAPTOTAJACE InhibitorTablet12.5 mgIII
Walburate (Valproate)VALBURTAJAntiepilepticTablet300 mgI
Potassium IodatePOTIOTAJ-IIodine SupplementTablet170 mgIII
MisoprostolMISOTAJProstaglandin AnalogTablet200 mcgI
AzithromycinAZITAJMacrolide AntibioticTablet500 mgII
Sulfadoxine + PyrimethamineSULPYTAJAntimalarialTablet500 mg + 25 mgII
ParacetamolPARATAJAnalgesic / AntipyreticTablet500 mgI
RebamipideREBAMITAJGastroprotectiveTablet100 mgIV
Trimetazidine MRTRIMETAZ-TAJ MRAnti-anginalModified-Release Tablet35 mgI

Highlights of the Unit-2 Product Grid

READY / ANDA-Approved Dossiers

These products are immediately licensable with full technical documentation:

  • Gabapentin Capsules
  • Levetiracetam Tablets
  • Colestipol Tablets
  • Diclofenac Potassium Tablets
  • Tizanidine Capsules
  • Desipramine Tablets
  • Isosorbide Mononitrate ER Tablets
  • Additional CNS, CV, and pain management products

These molecules demonstrate consistent demand, stable prescribing patterns, and strong public health relevance.


Stability Charged – Dossiers Ready

Products with completed or ongoing stability data, positioned for near-term submission:

  • Pimozide Tablets
  • Avatrombopag Tablets
  • Bismuth Subcitrate / Metronidazole / Tetracycline Capsules
  • Oxaprozin Capsules
  • Pyridostigmine Tablets

These assets are ideal for partners seeking medium-term exclusivity with differentiated portfolios.


Dossiers Planned by Q1–Q2 2026

Our development roadmap includes high-value combinations and specialty therapies:

  • Brivaracetam Tablets
  • Edoxaban Tablets
  • Amlodipine + Atorvastatin Fixed-Dose Combinations
  • Mesalamine Delayed-Release Tablets

These molecules address cardiovascular, neurological, and gastrointestinal disease burdens prevalent across West Africa.


Advanced Development and Prototype-Completed Products

Our advanced pipeline spans multiple high-growth segments:

  • Sacubitril + Valsartan
  • Rivaroxaban
  • Semaglutide (Oral)
  • Bempedoic Acid
  • Obeticholic Acid

These products position partners at the forefront of innovation, enabling entry into premium therapy segments.


Literature-Based and Early-Phase Pipeline

We continue to invest in next-generation therapies, including:

  • Resmetirom
  • Cenobamate
  • Finerenone
  • Lumateperone

These assets provide long-term strategic value for partners aiming to build future-ready portfolios.


Tailored Partnership Models for Senegal, Ivory Coast, and Mali

We offer customized collaboration structures, including:

  • Exclusive regional licensing
  • In-licensing of selected molecules
  • CMO / CDMO manufacturing
  • Joint commercialization
  • Royalty-based supply agreements

Our approach emphasizes regulatory efficiency, commercial sustainability, and shared growth.


Regulatory and Market Support

We actively support partners with:

  • Country-specific dossier adaptation
  • Labeling and artwork localization
  • Regulatory query resolution
  • Post-approval lifecycle management
  • Tender documentation support

This ensures smooth registration pathways and long-term compliance.


Why West African Partners Choose Taj Pharma

  • Proven manufacturing reliability
  • Deep and diversified product pipeline
  • Strong regulatory documentation
  • Flexible and transparent partnership terms
  • Commitment to long-term regional presence

Our objective is to build trusted, enduring partnerships that strengthen healthcare access across Senegal, Ivory Coast, and Mali.


Contact Taj Pharma India Ltd.

TAJ PHARMA INDIA LTD.
Plot No. 1019, Vill. Sarigam, G.I.D.C.
Road No. 10, Dist. Valsad,
Gujarat, India – 396155

Plant Location: https://g.co/kgs/WrD9gQQ

For Assistance, Contact:
+91 90995 11459
+91 99040 00567

We welcome your product interests, regulatory inquiries, and partnership discussions, and we would be pleased to schedule a detailed interaction at your convenience.